Table 1.
Quantity (ng) of 150 kDa BoNT-A in Dysport®, Botox®, and Xeomin®, analysed by ELISA using BoLISA® antibodies.
| Product | Batch | Expiry Date | Quantity of BoNT-A (ng/vial) | |
|---|---|---|---|---|
| Batch, Mean (SD) | Product, Mean (SD) | |||
| Dysport® 500 U | M00405 | Dec. 2018 | 2.73 (0.20) | 2.69 (0.03) |
| L24950 | Dec. 2018 | 2.66 (0.20) | ||
| L22072 | Oct. 2018 | 2.68 (0.23) | ||
| Botox® 100 U | C4321C3 | Sep. 2019 | 0.89 (0.12) | 0.90 (0.03) |
| C4289C3 | Sep. 2019 | 0.89 (0.10) | ||
| C4270C3 | Aug. 2019 | 0.94 (0.09) | ||
| Xeomin® 100 U | 694458 | Jul. 2019 | 0.41 (0.07) | 0.40 (0.01) |
| 696232 | Sep. 2019 | 0.40 (0.05) | ||
| 694788 | Sep. 2019 | 0.40 (0.05) | ||
BoNT-A, Botulinum neurotoxin type-A; ELISA, enzyme-linked immunosorbent assay; SD, standard deviation; U, units.